The German biotech firm said its lateral flow blood test does not detect subclinical HPV infection but picks up on HPV-induced cancers and pre-cancers.
The Warsaw, Poland-based firm has secured nearly €20 million ($23.7 million) this year to advance its PCR One point-of-care molecular diagnostic system.
The advent of high-throughput antigen testing is especially timely as global regions are suffering second and third waves of infections during the coronavirus pandemic, Ortho said.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
